Methods of predicting predisposition to or risk of kidney disease
Methods are disclosed herein for detecting a genetic predisposition to focal segmental glomerulosclerosis (FSGS) or hypertensive end-stage kidney disease (ESKD) or both in a human subject, e.g., by detecting the presence of at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. In a further embodiment, methods are disclosed for detecting resistance of a subject to a disease associated with Trypanosoma infection, e.g., by detecting at least one single nucleotide polymorphism (SNP) in an APOL1 gene, such as the C-terminal exon of an APOL1 gene. Also disclosed are methods for treating a subject infected with T. brucei . The methods include administering a therapeutically effective amount of an APOL1 protein including a S342G substitution, an I384M substitution, and/or a deletion of N388 and Y389 to the subject.
1. A method of producing a polymorphic profile of a human subject in need of screening for suitability as a kidney transplant donor, consisting of:
a) obtaining a nucleic acid sample from the kidney transplant donor;
b) contacting the nucleic acid sample with nucleic acid probes that specifically hybridize, respectively, to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 or a complement thereof, and/or nucleic acid primers that amplify, respectively, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 or a complement thereof; and
c) detecting the presence or absence of a G allele at single nucleotide polymorphism (SNP) rs73885319 in the nucleotide sequence of SEQ ID NO:1, the presence or absence of a G allele at SNP rs60910145 in the nucleotide sequence of SEQ ID NO:2, and the presence or absence of a six base pair deletion at SNP rs71785313 in the nucleotide sequence of SEQ ID NO:3,
thereby producing a polymorphic profile of the human subject.
2. A method of producing a polymorphic profile of a human kidney in need of screening for suitability as a transplantation organ, consisting of:
a) obtaining a nucleic acid sample from the human kidney;
b) contacting the nucleic acid sample with nucleic acid probes that specifically hybridize, respectively, to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 or a complement thereof, and/or nucleic acid primers that amplify, respectively, a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 or a complement thereof; and
c) detecting the presence or absence of a G allele at single nucleotide polymorphism (SNP) rs73885319 in the nucleotide sequence of SEQ ID NO:1, the presence or absence of a G allele at SNP rs60910145 in the nucleotide sequence of SEQ ID NO:2, and the presence or absence of a six base pair deletion at SNP rs71785313 in the nucleotide sequence of SEQ ID NO:3,
thereby producing a polymorphic profile of the human kidney.
3. The method of claim 2 , wherein the human kidney is in a human kidney donor.
4. The method of claim 2 , wherein the human kidney has been removed from a human kidney donor.
5. The method of claim 1 , wherein the sample is selected from the group consisting of whole blood, serum, buccal cells, extracted galls, biopsied or surgically removed tissue, tears, milk, a skin scrape, a surface washing, urine, sputum, cerebrospinal fluid, prostate fluid, pus, and a bone marrow aspirate.